Anson Funds Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Anson Funds Management’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-30,000	Closed	-$527K	–	483
2021 Q3	$527K	Buy	+30,000	New	+$350K	0.05%	245
2019 Q1	–	Sell	-174,174	Closed	-$298K	–	63
2018 Q4	$298K	Buy	+174,174	New	+$523K	0.17%	32

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Anson Funds Management's TRIL Position: Q4 2021 in Review

Anson Funds Management sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 30,000 shares — an estimated $527K sold.

Anson Funds Management first reported a position in TRIL in Q4 2018 and held it in 2 quarters. The position peaked at $527K in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Anson Funds Management reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Anson Funds Management sold 30,000 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $527K.
Anson Funds Management first reported a position in Trillium Therapeutics Inc. in Q4 2018 and held it in 2 quarters.
Anson Funds Management's Trillium Therapeutics Inc. position peaked at $527K in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Anson Funds Management's 13F filing for Q4 2021, filed 14 Feb 2022.